January 16, 2020
January 16, 2020 – The U.S. FDA has approved an update to the label for Rybelsus® (semaglutide) tablets, manufactured by Novo Nordisk. The label now includes data from the PIONEER 6 cardiovascular outcomes trial demonstrating cardiovascular safety.